Funding for this research was provided by:
Histiocytosis Association (2019-2020)
Received: 20 April 2021
Revised: 29 October 2021
Accepted: 4 November 2021
First Online: 16 November 2021
: ELD discloses editorial support from Pfizer Inc outside the submitted work. BHD has received research grants from the National Cancer Institute and the American Society of Hematology but declares no commercial conflicts of interest. FC and JH are investigators of an academic trial on the efficacy of cobimetinib on histiocytoses unrelated to the current manuscript. OA-W has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, Prelude Therapeutics, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., AIChemy, and Pfizer Boulder; OA-W has received prior research funding from H3B Biomedicine and LOXO Oncology unrelated to the current manuscript.